003850.KS
Latest Trade
15,300.00KRWChange
-300.00(-1.92%)Volume
266,381Today's Range
-
15,650.0052 Week Range
-
16,700.00As of on the Korea Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 15,600.00 |
|---|---|
Open | 15,450.00 |
Volume | 266,381 |
3M AVG Volume | 6.89 |
Today's High | 15,650.00 |
Today's Low | 15,200.00 |
52 Week High | 16,700.00 |
52 Week Low | 9,490.00 |
Shares Out (MIL) | 42.04 |
Market Cap (MIL) | 676,260.00 |
Forward P/E | 18.61 |
Dividend (Yield %) | -- |
S.Korea's Boryung Pharm Says Co-CEO Kim Eun-Sun Resigns For Personal Reason, Appoints An Jae-Hyun As New Co-CEO
Boryung Pharm to buy back shares at 5.57 bln won
Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
Boryung Pharmaceutical Co.,Ltd. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company’s products include antibiotics, dermatology drugs, cardiovascular drugs, antineoplastics, antiemetics, urology drugs, gastrointestinal drugs, antipyretic drugs, analgesics, anti-inflammatory drugs, amino acids injections, dialysis drugs, antidiabetics, central nervous system (CNS) drugs, vaccines and others. It also provides active pharmaceutical ingredients (API) products, including doxorubicin hydrochloride, epirubicin hydrochloride, captopril, alacepril, nitrendipine, fluconazole, ondansetron hydrochloride, tamsulosin hydrochloride, glimepiride, torsemide and others.
Industry
Biotechnology & Drugs
Executive Leadership
Eun Seon Kim
Chairman of the Board
Seung Ho Kim
Chairman
Jae Hyeon Ahn
Co-Chief Executive Officer, Director
Sam Su Lee
Co-Chief Executive Officer, Director
Yong Gwan Jeon
Vice President
Price To Earnings (TTM) | 19.52 |
|---|---|
Price To Sales (TTM) | 1.36 |
Price To Book (MRQ) | 2.29 |
Price To Cash Flow (TTM) | 13.98 |
Total Debt To Equity (MRQ) | 34.05 |
LT Debt To Equity (MRQ) | 26.76 |
Return on Investment (TTM) | 9.67 |
Return on Equity (TTM) | 6.86 |
* AGREES TO TERMINATE 85 BILLION WON ($70.09 million) WORTH CONTRACT WITH NOVARTIS' UNIT IN SOUTHEAST ASIA Source text for Eikon: https://bit.ly/2NwTDEF Further company coverage: ($1 = 1,212.6600 won)
* Says it will repurchase 100,000 common shares worth 5.57 billion won
* SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA
* Says it signed 70.25 billion won contract to provide products
* Says it signed a 42.18 billion won contract with Kiara Health(PTY) Ltd to provide products
* Says it will pay annual cash dividend as 200 won/share for FY 2016, to shareholders of record on Dec. 31, 2016
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.